CA IX Targeting Conjugates for SPECT Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for targeting therapeutics to carbonic anhydrase IX (CA IX) expressing cancers are limited, with little research on small molecule CA IX ligands conjugated to potent anti-cancer drugs in vivo, and a need for further selective imaging agents beyond PET and fluorescence.
Innovation Solution
Development of conjugates comprising a CA IX ligand covalently bound to therapeutic or imaging agents via a linker, specifically aryl sulfonamide compounds, for targeted delivery and imaging of CA IX expressing cancers using SPECT imaging.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule CA IX ligands are conjugated to potent anti-cancer drugs, then therapeutic efficacy is improved, but research and development progress is limited due to lack of in vivo studies
Solution Approach 1:
The patent performs preliminary in vivo studies in xenograft models before clinical application, establishing the safety and efficacy profile of CA IX-targeted small molecule conjugates. This preliminary action enables subsequent research and development by providing preclinical data support.
2Measurement precision
If conventional imaging agents (PET and fluorescence) are used, then imaging capability is achieved, but selectivity and variety are limited
Solution Approach 1:
The patent introduces SPECT imaging as a new modality with different physical parameters (gamma ray detection) compared to conventional PET and fluorescence imaging. This parameter change expands the variety of available imaging agents and provides alternative imaging options for CA IX-targeted therapy.
3Reliability
If CA IX targeting conjugates are developed, then cancer treatment specificity is improved, but device and methodology complexity increases
Solution Approach 1:
The patent uses CA IX-specific small molecule ligands as intermediaries to bridge the gap between the targeting function and the therapeutic agent. These ligands bind to CA IX on the cancer cell surface and serve as mediators for delivering the therapeutic payload specifically to hypoxic tumor regions.
Solution Approach 2:
The conjugate is segmented into distinct functional modules: a CA IX-targeting ligand portion, a linker portion, and a therapeutic agent portion. This segmentation allows for independent optimization of each component and facilitates modular design of different conjugate variants.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugates enable effective targeting and imaging of CA IX expressing cancers, providing a novel approach for both therapeutic and diagnostic applications, enhancing the specificity and efficacy of cancer treatment and imaging.
Implementation Method 1
CA IX-specific ligands have been used to image mouse xenograft models of colon, renal and cervical cancers
Implementation Method 2
The present disclosure also relates to the use of targeting conjugates of carbonic anhydrase IX inhibitors in SPECT imaging methods
Data Source
AI summary
The present disclosure relates to compositions and methods of carbonic anhydrase IX inhibitors. The present disclosure also relates to targeting conjugates of carbonic anhydrase IX inhibitors. The present disclosure also relates to the use of targeting conjugates of carbonic anhydrase IX inhibitors in SPECT imaging methods.